摘要
国内外对早产儿视网膜病变(retinopathy of prematurity,ROP)的预防都是通过对高危早产儿进行筛查,并对发现的早期病变及时治疗。广角数码儿童视网膜成像系统(RetCam)和抗血管内皮生长因子(vascular endothelial growth factor,VEGF)玻璃体内注射为ROP筛查和治疗带来了巨大进步。但是,目前我国在ROP筛查和治疗中仍存在很多不规范之处,本文就多年来筛查中遇见的问题作一总结。新生儿眼病筛查是随着RetCam普及而开展的,此项工作近几年只在一些有条件的地区、妇幼保健机构、医疗机构逐渐开展,其规范性和成本效益分析尚在研究中,本文根据自己的实践经验介绍一份筛查指南。[眼科新进展,2014,34(2):101-107]
In China or abroad,the prevention of retinopathy of prematurity （ROP） is to screen high risk preterm infants and perform diode laser photocoagulation for pre- threshold type 1 ROP by binocular indirect ophthalmoscope. Pediatric wide field digital imaging system （RetCam）and anti-vascular endothelial growth factor （VEGF）intraocu- lar injection brought a great progress for ROP screening and treatment. However, there are much non-standard practices in ROP screening and treatment in China. This paper summarized all problems accounted in ROP screening for many years. Recently, as Ret- Cam equipment popularized in some districts and hospitals, neonatal ocular disease uni- versal screening develop. But its standard and cost-benefit is still not clear. This paper Introduces a guideline for ROP and neonatal ocular disease screening according to our practical ex-oerience.
出处
《眼科新进展》
CAS
北大核心
2014年第2期101-107,共7页
Recent Advances in Ophthalmology
基金
深圳市国际合作项目(编号:GJHZ20120618115256900)~~
关键词
早产儿视网膜病变
早产儿
新生儿
筛查
retinopathy of prematurity
preterm infants
neonate
screening
